Nitrosamine impurities are potentially genotoxic which are considered under cohort of concern as per ICH M7 guidelines and need to be controlled at trace levels during quantification in drug substances and drug products for safe human consumption. Recent regulatory requirements also suggest the need to have highly sensitive analytical methods for the accurate quantification of Nitrosamine impurities. In this paper we have presented simple, rapid and ultra-sensitive LC-MS/MS method for six potential genotoxic nitrosamine impurities: N-Nitroso dimethyl amine (NDMA), N-Nitroso diethyl amine (NDEA), N-Nitroso Ethyl Iso propylamine (NEIPA), N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) N-Nitroso diisopropylamino (NDIPA) and N-Nitroso dibutyl amine (NDBA) with a LOQ of 0.004 ppm. Chromatographic separation is achieved using Zorbax SB C18 150 × 3.0 mm, 3.5 μ column with 0.1% formic acid in water as mobile phase A and 0.1% formic acid in methanol as mobile phase B at a flow rate of 0.3 ml/min using gradient mode of elution at a total run time of 18 minutes. Six nitrosamine impurities are successfully ionized and quantified in positive mode of atmospheric pressure chemical ionization (APCI) using multiple reaction monitoring (MRM). Method validation is performed as per ICH guidelines evaluating the limit of quantification and detection and found to give good S/N ratios with good linearity range of 0.002 - 2 ppm with regression coefficient >0.99 for all the six nitrosamine impurities. Method recoveries are established using three-step sample preparation protocol and are found to be satisfactory within 80% - 120%. The method can be used routinely applied for the detection of Nitrosamines in Telmisartan at a concentration of 1.5 ng/ml (0.03 ppm with respect to telmisartan concentration of 50 mg/ml).
References
[1]
U.S. Food and Drug Administration (2008) Guidelines for Industry; Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches (Draft). U.S. Food and Drug Administration, Silver Spring.
[2]
United States Department of Health and Human Services, Food and Drug Administration (2008) Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. United States Department of Health and Human Services, Food and Drug Administration, Silver Spring.
[3]
Note for Guidance on Pharmaceutical Development, EMEA/CHMP/167068/2004.
[4]
ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. European Medicines Agency, London.
[5]
Mirvish, S.S. (1975) Formation of N-Nitroso Compounds: Chemistry, Kinetics, and in Vivo Occurrence. Toxicology and Applied Pharmacology, 31, 325-351. https://doi.org/10.1016/0041-008X(75)90255-0
[6]
Mitch, W.A. and Sedlak, D.L. (2002) Formation of N-Nitrosodimethylamine (NDMA) from Dimethylamine during Chlorination. Environmental Science & Technology, 36, 588-595. https://doi.org/10.1021/es010684q
[7]
U.S. Food and Drug Administration (2019) FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan). https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
[8]
European Medicines Agency (2018) EMA 485921. Update on Review of Valsartan Medicines Following Detection of Impurity in Active Substance, EMA/485921/2018. European Medicines Agency, London.
[9]
European Medicines Agency (2018) EMA 643116. EMA Review of Impurities in Sartan Medicines. EMA/643116/2018, European Medicines Agency, London.
[10]
U.S. Food and Drug Administration (2021) Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry. U.S. Food and Drug Administration, Silver Spring. https://www.fda.gov/media/141720/download
[11]
Bergovac, M., Knezevic, A., Plavec, D. and Trkulja, V. (2009) Telmisartan in Daily Clinical Practice: Factors Affecting Efficacy in Treatment of Primary Arterial Hypertension. Journal of Postgraduate Medicine, 55, 27-32. https://doi.org/10.4103/0022-3859.43547
[12]
Jugdutt, B.I. (2010) Clinical Effectiveness of Telmisartan Alone or in Combination Therapy for Controlling Blood Pressure and Vascular Risk in the Elderly. Clinical Interventions in Aging, 5, 403-416. https://doi.org/10.2147/CIA.S6709
[13]
Gosse, P. (2006) A Review of Telmisartan in the Treatment of Hypertension: Blood Pressure Control in the Early Morning Hours. Vascular Health and Risk Management, 2, 195-201.
[14]
Ohishi, M., Kawai, T., Hayashi, N., Kitano, S., Katsuya, T., Nagano, M., Hirotani, A., Yamamoto, K., Kamide, K. and Rakugi, H. (2013) Effect of Tablets with a Combination of Telmisartan and Amlodipine on Patients with hypertension: The Cotalo study. Hypertension Research, 36, 620-626. https://doi.org/10.1038/hr.2013.10
[15]
U.S. Food and Drug Administration (2019) Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs. U.S. Food and Drug Administration, Silver Spring. https://www.fda.gov/media/125478/download
[16]
U.S. Food and Drug Administration (2020) Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product. U.S. Food and Drug Administration, Silver Spring. https://www.fda.gov/media/138617/download
[17]
Chemisches Und Veterinäruntersuchungsamt Karlsruhe (2018) Test Method for the Determination of NDMA by LC/MS/MS in Valsartan Finished Products. Chemisches Und Veterinäruntersuchungsamt Karlsruhe, Karlsruhe. https://www.edqm.eu/sites/default/files/omcl-method-determination-ndma-valsartan-cvua-september2018.pdf
[18]
Djintchui Ngongang, A., Duy, S.V. and Sauvé, S. (2015) Analysis of Nine N-Nitrosamines Using Liquid Chromatography-Accurate Mass High Resolution-Mass Spectrometry on a Q-Exactive Instrument. Analytical Methods, 7, 5748-5759. https://doi.org/10.1039/C4AY02967D
[19]
Ripollés, C., Pitarch, E., Sancho, J.V., López, F.J. and Hernández, F. (2011) Determination of Eight Nitrosamines in Water at the ng L-1 Levels by Liquid Chromatography Coupled to Atmospheric Pressure Chemical Ionization Tandem Mass Spectrometry. Analytica Chimica Acta, 702, 62-71. https://doi.org/10.1016/j.aca.2011.06.024
[20]
Cohen, J.B. and Bachman, J.D. (1978) Measurement of Environmental Nitrosamines. IARC Scientific Publications, No. 19, 357-372.
[21]
Wang, W., Hu, J., Yu, J. and Yang, M. (2010) Determination of N-Nitroso Dimethylamine in drinking Water by UPLC-MS/MS. Journal of Environmental Sciences (China), 22, 1508-1512. https://doi.org/10.1016/S1001-0742(09)60281-3
[22]
Chang, S.-H., Chang, C.-C., Wang, L.-J., Chen, W.-C., Fan, S.-Y., Zang, C.-Z., Hsu, Y.H., Lin, M.-C., Tseng, S.-H. and Wang, D.-Y. (2020) A Multi-Analyte LC-MS/MS Method for Screening and Quantification of Nitrosamines in Sartans. Journal of Food and Drug Analysis, 28, 292-301. https://doi.org/10.38212/2224-6614.1063
[23]
Parr, M.K. and Joseph, J.F. (2019) NDMA Impurity in Valsartan and Other Pharmaceutical Products: Analytical Methods for the Determination of N-Nitrosamines. Journal of Pharmaceutical and Biomedical Analysis, 164, 536-549. https://doi.org/10.1016/j.jpba.2018.11.010
